Your browser is no longer supported. Please, upgrade your browser.
Settings
EVLO [NASD]
Evelo Biosciences, Inc.
Index- P/E- EPS (ttm)-2.42 Insider Own0.45% Shs Outstand46.76M Perf Week-5.37%
Market Cap534.43M Forward P/E- EPS next Y-2.02 Insider Trans128.49% Shs Float27.00M Perf Month-11.07%
Income-93.70M PEG- EPS next Q-0.51 Inst Own80.40% Short Float10.88% Perf Quarter-22.95%
Sales- P/S- EPS this Y11.10% Inst Trans6.11% Short Ratio11.73 Perf Half Y91.60%
Book/sh0.65 P/B15.45 EPS next Y2.90% ROA-95.40% Target Price- Perf Year169.89%
Cash/sh- P/C- EPS next 5Y- ROE-197.70% 52W Range3.55 - 19.93 Perf YTD-16.96%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-49.62% Beta-
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin- 52W Low182.82% ATR1.04
Employees90 Current Ratio3.60 Sales Q/Q- Oper. Margin- RSI (14)35.99 Volatility5.97% 9.58%
OptionableYes Debt/Eq0.98 EPS Q/Q11.80% Profit Margin- Rel Volume0.38 Prev Close10.02
ShortableYes LT Debt/Eq0.98 EarningsMar 09 BMO Payout- Avg Volume250.25K Price10.04
Recom2.50 SMA20-14.65% SMA50-25.24% SMA20024.75% Volume97,204 Change0.20%
Dec-23-20Initiated JMP Securities Mkt Outperform $27
May-21-20Downgrade Morgan Stanley Overweight → Equal-Weight $8
May-12-20Downgrade Jefferies Buy → Hold $18 → $6
Apr-30-19Initiated Jefferies Buy $18
Jan-29-19Initiated Chardan Capital Markets Neutral $10
Apr-05-21 07:00AM  
Mar-30-21 09:30AM  
Mar-23-21 03:00AM  
Mar-09-21 05:00PM  
07:00AM  
05:30AM  
Mar-02-21 07:00AM  
Feb-16-21 07:00AM  
Jan-28-21 09:08PM  
04:01PM  
Jan-21-21 08:05AM  
Jan-20-21 07:00AM  
Jan-07-21 07:00AM  
Dec-23-20 10:07AM  
Dec-21-20 07:00AM  
Dec-14-20 11:21PM  
Dec-09-20 09:00AM  
07:00AM  
Dec-03-20 07:00AM  
Nov-27-20 10:47AM  
Nov-10-20 09:41AM  
Nov-09-20 08:00AM  
Oct-29-20 07:00AM  
06:30AM  
Oct-22-20 04:01PM  
Oct-15-20 07:00AM  
Oct-14-20 07:00AM  
Oct-13-20 07:00AM  
Oct-12-20 09:00AM  
Sep-14-20 07:06AM  
Sep-08-20 07:00AM  
Jul-30-20 07:00AM  
Jul-23-20 07:00AM  
Jul-07-20 08:00AM  
Jul-01-20 07:08AM  
Jun-24-20 07:56PM  
04:01PM  
Jun-22-20 02:00AM  
Jun-16-20 07:00AM  
May-29-20 12:00PM  
May-28-20 08:00AM  
07:00AM  
May-27-20 12:34PM  
11:30AM  
May-14-20 02:58PM  
May-11-20 07:00AM  
May-07-20 07:00AM  
May-04-20 09:00AM  
Apr-15-20 07:00AM  
Mar-05-20 07:00AM  
Mar-02-20 07:00AM  
Feb-25-20 12:09PM  
07:00AM  
Feb-13-20 07:00AM  
Feb-06-20 08:00AM  
Jan-10-20 07:00AM  
Dec-20-19 06:39PM  
Dec-19-19 08:00AM  
Dec-05-19 07:00AM  
Nov-13-19 08:01AM  
Nov-08-19 07:00AM  
Nov-05-19 07:01AM  
07:00AM  
Oct-29-19 08:00AM  
Sep-26-19 04:05PM  
Sep-20-19 07:00AM  
Sep-17-19 07:00AM  
Sep-03-19 08:00AM  
Aug-06-19 10:24PM  
07:01AM  
07:00AM  
Jul-30-19 08:00AM  
Jul-25-19 08:00AM  
Jul-15-19 08:00AM  
May-30-19 08:00AM  
May-27-19 10:29AM  
May-15-19 08:00AM  
May-08-19 02:23PM  
May-04-19 04:23PM  
May-02-19 07:00AM  
Apr-25-19 07:30AM  
Apr-03-19 08:00AM  
Mar-04-19 07:30AM  
Feb-14-19 07:00AM  
Feb-07-19 08:00AM  
Jan-28-19 06:00AM  
Jan-04-19 06:00AM  
Dec-05-18 08:00AM  
Nov-27-18 08:00AM  
Nov-26-18 08:00AM  
Nov-13-18 08:10AM  
Nov-07-18 08:00AM  
Nov-01-18 08:00AM  
Sep-06-18 08:00AM  
Aug-02-18 08:00AM  
Jun-25-18 08:00AM  
Jun-15-18 06:28PM  
Jun-14-18 08:00AM  
Jun-04-18 08:53AM  
May-31-18 08:00AM  
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flagship Ventures Fund IV Gene10% OwnerFeb 02Buy15.00130,0001,950,0004,125,461Feb 04 05:56 PM
Epstein David RDirectorDec 11Buy6.667,70051,26117,700Dec 14 05:15 PM
Liu Xiaoli JacquelinePrincipal Accounting OfficerDec 01Sale5.173,00015,5100Dec 02 04:44 PM
Epstein David RDirectorAug 31Buy4.495,75225,80410,000Sep 01 04:13 PM
Epstein David RDirectorAug 28Buy4.394,24818,6314,248Sep 01 04:13 PM
Flagship Ventures Fund IV Gene10% OwnerJun 29Buy3.754,666,66617,499,9984,079,032Jul 01 05:24 PM